title: Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFNβ transgenic mice.
abstract: The pathogenetic mechanisms underlying gastrointestinal dysmotility in diabetic patients remain poorly understood, although enteric neuropathy, damage to interstitial cells of Cajal (ICC) and smooth muscle cell injury are believed to play a role. The aim of this study was to investigate the morphological and functional changes underlying intestinal dysmotility in RIP-I/hIFNβ transgenic mice treated with multiple very low doses of streptozotocin (20 mg/kg, i.p., 5 days). Compared with vehicle-treated mice, streptozotocin-treated animals developed type 1 diabetes mellitus, with sustained hyperglycaemia for 3.5 months, polyphagia, polydipsia and increased faecal output without changes in faecal water content (metabolic cages). Diabetic mice had a longer intestine, longer ileal villi and wider colonic crypts (conventional microscopy) and displayed faster gastric emptying and intestinal transit. Contractility studies showed selective impaired neurotransmission in the ileum and mid-colon of diabetic mice. Compared with controls, the ileal and colonic myenteric plexus of diabetic mice revealed ultrastructural features of neuronal degeneration and HuD immunohistochemistry on whole-mount preparations showed 15% reduction in neuronal numbers. However, no immunohistochemical changes in apoptosis-related markers were noted. Lower absolute numbers of neuronal nitric oxide synthase- and choline acetyltransferase-immunopositive neurons and enhanced vasoactive intestinal polypeptide and substance P immunopositivity were observed. Ultrastructural and immunohistochemical analyses did not reveal changes in the enteric glial or ICC networks. In conclusion, this model of diabetic enteropathy shows enhanced intestinal transit associated with intestinal remodelling, including neuroplastic changes, and overt myenteric neuropathy. Such abnormalities are likely to reflect neuroadaptive and neuropathological changes occurring in this diabetic model.
authors: Department of Animal Medicine and Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain. anna.domenech@uab.es
authors: Anna
authors: A
authors: Domènech
authors: Gianandrea
authors: G
authors: Pasquinelli
authors: Roberto
authors: R
authors: De Giorgio
authors: Alessandra
authors: A
authors: Gori
authors: Fàtima
authors: F
authors: Bosch
authors: Martí
authors: M
authors: Pumarola
authors: Marcel
authors: M
authors: Jiménez
mesh_terms: D000818:Animals; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D003106:Colon / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D003929:Diabetic Neuropathies / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D005746:Gastric Emptying / Q000502:physiology; D005769:Gastrointestinal Motility / Q000502:physiology*; D007082:Ileum / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D016899:Interferon-beta / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009197:Myenteric Plexus / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D052248:Nitric Oxide Synthase Type I / Q000378:metabolism; D053422:Receptor-Interacting Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D013311:Streptozocin / Q000009:adverse effects; D013373:Substance P / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism
chemical_list: D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D013311:Streptozocin; D016899:Interferon-beta; D052248:Nitric Oxide Synthase Type I; D002795:Choline O-Acetyltransferase; D053422:Receptor-Interacting Protein Serine-Threonine Kinases